Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERAVANCE BIOPHARMA, INC.

(TBPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Edge Higher Premarket Wednesday

09/15/2021 | 09:12am EST


ę MT Newswires 2021
All news about THERAVANCE BIOPHARMA, INC.
11/18Theravance Biopharma to Participate in an Upcoming Investor Conference
PR
11/16THERAVANCE BIOPHARMA, INC. : Other Events (form 8-K)
AQ
11/16Theravance Biopharma, Inc. Announces to Voluntarily Discontinued Its Phase 2 Study of i..
CI
11/08THERAVANCE BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/05JPMorgan Upgrades Theravance Biopharma to Neutral From Underweight, Lifts Price Target ..
MT
11/03THERAVANCE BIO : Q3 Earnings Snapshot
AQ
11/03Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Bu..
PU
11/03Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q3 Revenue $13.2M, vs. Street Est of $..
MT
11/03Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/03Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Bu..
PR
More news
Analyst Recommendations on THERAVANCE BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 53,7 M - -
Net income 2021 -196 M - -
Net Debt 2021 423 M - -
P/E ratio 2021 -3,00x
Yield 2021 -
Capitalization 619 M 619 M -
EV / Sales 2021 19,4x
EV / Sales 2022 13,2x
Nbr of Employees 359
Free-Float 83,4%
Chart THERAVANCE BIOPHARMA, INC.
Duration : Period :
Theravance Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERAVANCE BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 8,40 $
Average target price 10,13 $
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Rick E. Winningham Chairman & Chief Executive Officer
Andrew Asa Hindman Chief Financial Officer & Senior Vice President
Philip D. Worboys Senior VP-Research & Translational Science
Vijay Sabesan Senior Vice President-Technical Operations
Burton Gordon Malkiel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
THERAVANCE BIOPHARMA, INC.-52.73%619
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871